Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Standard
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. / Valero, Vicente; Forbes, John; Pegram, Mark D; Pienkowski, Tadeusz; Eiermann, Wolfgang; von Minckwitz, Gunter; Roche, Henri; Martin, Miguel; Crown, John; Mackey, John R; Fumoleau, Pierre; Rolski, Janusz; Mrsic-Krmpotic, Zrinka; Jagiello-Gruszfeld, Agnieszka; Riva, Alessandro; Buyse, Marc; Taupin, Henry; Sauter, Guido; Press, Michael F; Slamon, Dennis J.
In: J CLIN ONCOL, Vol. 29, No. 2, 2, 2011, p. 149-156.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
AU - Valero, Vicente
AU - Forbes, John
AU - Pegram, Mark D
AU - Pienkowski, Tadeusz
AU - Eiermann, Wolfgang
AU - von Minckwitz, Gunter
AU - Roche, Henri
AU - Martin, Miguel
AU - Crown, John
AU - Mackey, John R
AU - Fumoleau, Pierre
AU - Rolski, Janusz
AU - Mrsic-Krmpotic, Zrinka
AU - Jagiello-Gruszfeld, Agnieszka
AU - Riva, Alessandro
AU - Buyse, Marc
AU - Taupin, Henry
AU - Sauter, Guido
AU - Press, Michael F
AU - Slamon, Dennis J
PY - 2011
Y1 - 2011
N2 - Docetaxel-trastuzumab (TH) is effective therapy for HER2-amplified metastatic breast cancer (MBC). Preclinical findings of synergy between docetaxel, carboplatin, and trastuzumab (TCH) prompted a phase III randomized trial comparing TCH with TH in patients with HER2-amplified MBC.
AB - Docetaxel-trastuzumab (TH) is effective therapy for HER2-amplified metastatic breast cancer (MBC). Preclinical findings of synergy between docetaxel, carboplatin, and trastuzumab (TCH) prompted a phase III randomized trial comparing TCH with TH in patients with HER2-amplified MBC.
KW - Humans
KW - Female
KW - Middle Aged
KW - Disease-Free Survival
KW - Neoplasm Metastasis
KW - Gene Amplification
KW - Antibodies, Monoclonal, Humanized
KW - Receptor, erbB-2/genetics
KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
KW - Antibodies, Monoclonal/administration & dosage/adverse effects
KW - Breast Neoplasms/drug therapy/enzymology/genetics/pathology
KW - Carboplatin/administration & dosage/adverse effects
KW - Taxoids/administration & dosage/adverse effects
KW - Humans
KW - Female
KW - Middle Aged
KW - Disease-Free Survival
KW - Neoplasm Metastasis
KW - Gene Amplification
KW - Antibodies, Monoclonal, Humanized
KW - Receptor, erbB-2/genetics
KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
KW - Antibodies, Monoclonal/administration & dosage/adverse effects
KW - Breast Neoplasms/drug therapy/enzymology/genetics/pathology
KW - Carboplatin/administration & dosage/adverse effects
KW - Taxoids/administration & dosage/adverse effects
M3 - SCORING: Journal article
VL - 29
SP - 149
EP - 156
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 2
M1 - 2
ER -